Table 2. Stroke characteristics.
| Characteristic | Values |
|---|---|
| Time to treatment (min) with rt-PA, median (IQR) | 159.0 (125.0–180.0) |
| Duration of thrombolysis treatment (min), median (IQR) | 60.0 (60.0–64.0) |
| Dose of rt-PA, (mg±SD) | |
| Intravenous rt-PA | 67.6±15.5 |
| Bridging (combined intravenous and intraarterial) | 68.0±12.5 |
| Stroke etiology (TOAST), n (%) | |
| Large-artery atherosclerosis | 46 (38.3) |
| Small-vessel occlusion | 14 (11.7) |
| Cardioembolic | 23 (19.2) |
| Other/undetermined | 37 (30.8) |
| Stroke severity on admission, n (%) | |
| NIHSS 0–5 | 35 (29.2) |
| NIHSS 6–10 | 44 (36.7) |
| NIHSS 11–15 | 18 (15.0) |
| NIHSS >15 | 21 (17.5) |
| Undetermined | 2 (1.6) |
| Short-term functional outcome, n (%) | |
| Favourable | 48 (40.0) |
| No change | 43 (35.8) |
| Unfavourable | 17 (14.2) |
| Death | 5 (4.2) |
| Undetermined | 7 (5.8) |
| Haemorrhagic transformation (ECASS II), n (%) | 13 (10.8) |
| aSICH | 7 (5.8) |
| SICH | 6 (5.0) |
| Mortality by day 7, n (%) | |
| Survival | 115 (95.8) |
| Death | 5 (4.2) |
| Mortality by day 14, n (%) | |
| Survival | 105 (87.5) |
| Death | 15 (12.5) |
| Long-term functional outcome at 3months, n (%) | |
| mRS 0–1 | 41 (34.2) |
| mRS 2–5 | 30 (25.0) |
| mRS 6 (death) | 26 (21.7) |
| Undetermined | 23 (19.1) |
| Imaging data (median, total range) | |
| ASPECTS on admission | 10.0 (7.0–10.0) |
| ASPECTS at 24 h | 9.0 (0.0–10.0) |
rt-PA: recombinant tissue type plasminogen activator, TOAST: Trial of Org 10172 in
Acute Stroke Treatment, NIHSS: National Institute of Health Stroke Scale, ECASS II: European Cooperative Acute Stroke Study II, aSICH: asymptomatic intracranial hemorrhage, SICH: symptomatic intracranial hemorrhage, mRS: modified Rankin Scale, ASPECTS: Alberta Stroke Program Early CT Score.